PubMed · 5190376
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J P Chauvin. [Angina pectoris].. https://pubmed.ncbi.nlm.nih.gov/5190376/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
As with any new test, novel cardiac markers must meet basic analytical and clinical performance issues. For sensitivity and specificity, it is important to know what protein forms are released into blood after injury, and which of these forms are measured by the assays in question. When commercial tests become available, the choice of the measurement platform will be important in the timely delivery of results. The cut-off concentration used is also important, and requires careful selection of the patient groups to be studied. If the intent of the marker is to be used to diagnose acute myocardial infarction (AMI), data from normal subjects should not be included. However, low cut-off limits can be useful for detection of minor myocardial injury if the new assay is highly sensitive and specific. New tests are needed in the area of early diagnosis of AMI, detection of reinfarction or myocardial extension after AMI, risk stratification of patients with unstable angina, and therapeutic monitoring of patients with congestive heart failure. The most promising new markers are glycogen phosphorylase BB, free fatty acid binding protein, and brain natriuretic peptide.
Glycogen phosphorylase isoenzyme BB (GPBB) is a key enzyme of glycogenolysis. Its degree of association with the sarcoplasmatic reticulum glycogenolysis complex depends essentially on the metabolic state of the myocardium. With the onset of tissue hypoxia, when glycogen is broken down, GPBB is converted from a structurally bound into a cytoplasmatic form. Considerable amounts of GPBB are only found in human heart and brain. In the first clinical studies GPBB was the most sensitive marker for the diagnosis of acute myocardial infarction within 4 h of chest pain onset. GPBB also increases early in patients with unstable angina and reversible ST-T alterations in the resting electrocardiogram at hospital admission, which could be useful for risk stratification. GPBB is sensitive for the detection of perioperative ischaemic myocardial damage and infarction in patients undergoing coronary artery bypass grafting. The diagnostic specificity of GPBB in non-traumatic chest pain patients was comparable to creatine kinase MB. These results indicate that GPBB is a sensitive marker for ischaemic myocardial damage.